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Background and Purpose: To identify factors associated with prior stroke at
presentation in patients with cryptogenic stroke (CS) and patent foramen ovale (PFO).
Methods: We studied cross-sectional data from the International PFO Consortium
Study (NCT00859885). Patients with first-ever stroke and those with prior stroke at
baseline were analyzed for an association with PFO-related (right-to-left shunt at rest,
atrial septal aneurysm, deep venous thrombosis, pulmonary embolism, and Valsalva
maneuver) and PFO-unrelated factors (age, gender, BMI, hypertension, diabetes mellitus,
hypercholesterolemia, smoking, migraine, coronary artery disease, aortic plaque). A
multivariable analysis was used to adjust effect estimation for confounding, e.g., owing
to the age-dependent definition of study groups in this cross-sectional study design.
Results: We identified 635 patients with first-ever and 53 patients with prior stroke. Age,
BMI, hypertension, diabetes mellitus, hypercholesterolemia, coronary artery disease, and
right-to-left shunt (RLS) at rest were significantly associated with prior stroke. Using
a pre-specified multivariable logistic regression model, age (Odds Ratio 1.06), BMI
(OR 1.06), hypercholesterolemia (OR 1.90) and RLS at rest (OR 1.88) were strongly
associated with prior stroke.Based on these factors, we developed a nomogram to
illustrate the strength of the relation of individual factors to prior stroke.
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Conclusion: In patients with CS and PFO, the likelihood of prior stroke is associated
with both, PFO-related and PFO-unrelated factors.
Keywords: patent foramen ovale, PFO, right-to-left shunt, cryptogenic stroke, prior stroke, risk factor,
hypercholesterolemia, International PFO Consortium
INTRODUCTION
The prevalence of patent foramen ovale (PFO) in the general
adult population is 15–35% (1) and its association with
cryptogenic stroke (CS) has been clearly established (2, 3). The
higher prevalence of PFO in CS of all ages (3, 4) suggests
a pathogenic role for PFO, at least in a substantial portion
of these patients. Assuming that paradoxical embolism is the
predominant pathogenic mechanism for recurrent strokes (5),
PFO closure is a logical treatment option. However, recent
RCTs comparing percutaneous closure with antithrombotic
treatment revealed inconsistent results—some of them in favor
of closure (6–9), whereas others without a significant advantage
of closure (10–13). Low recurrence rates under both prevention
regimens, non-PFO related recurrent stroke mechanisms,
crossovers, procedure- and device-related complications as
well as suboptimal patient selection—i.e., including some
patients with non-PFO-related index strokes—might explain the
inconsistency of the results (14–17). Hence, in patients with PFO
and CS, the risk of stroke recurrence may be associated with both
PFO-related and PFO-unrelated factors.
Previous strokes at presentation have been identified as a risk
factor for stroke recurrence in patients with CS and PFO (18).
The aim of this study was to identify PFO-related and -
unrelated risk factors associated with prior stroke in CS patients.
Furthermore, we developed a nomogram to illustrate the strength
of these associations.
METHODS
Patients
The International PFO Consortium is an ongoing academic
trial, where researchers from currently nineteen stroke centers
worldwide collaborate (NCT00859885). It was founded in 2008
and collects data of patients with ischemic stroke or TIA and
PFO. Emphasis is placed on the evaluation of risk factors, PFO
diagnosis, and secondary stroke prevention. It is a multicenter
prospective study with a scheduled yearly follow-up. Database
is expected to be closed after all patients reach a minimum of
three years follow-up in 2021. Ethical approval was obtained
from the local ethics committee of the corresponding center if
legally required.
Patients older than 18 years with ischemic stroke or TIA ≤3
months and proven PFO on transesophageal echocardiography
are eligible for the International PFO Consortium Study. There
was no upper age limit. The whole International PFO consortium
cohort included patients with different stroke etiologies. In the
current study we addressed those with an undetermined stroke
etiology, i.e., CS. Baseline data comprise demographic data,
vascular risk factors, conditions predisposing to paradoxical
embolism, previous medication, brain CT or MRI findings,
echocardiographic PFO-features, and stroke etiology according
to TOAST criteria (19). Annual follow-up visits assess secondary
stroke prevention and stroke recurrence. Vascular risk factors
include age, gender, arterial hypertension, diabetes mellitus,
hypercholesterolemia, smoking, self-reportedmigraine, coronary
artery disease, previous stroke, thrombophilia (factor V Leiden
and prothrombin mutation, protein C and S deficiency, AT3
deficiency, and antiphospholipid antibodies). Echocardiographic
features include atrial septal aneurysm (ASA) defined as
hypermobility of the atrial septum with an excursion of >10mm
from midline, aortic plaques >4mm thickness, and right-to-
left shunt (RLS) at rest or under Valsalva maneuver (VM).
Conditions predisposing to paradoxical embolism comprise VM
at the time of stroke onset, deep vein thrombosis (DVT), and
pulmonary embolism.
From September 2008 through December 2014, the
International PFO Consortium enrolled 931 patients with CS
and PFO. The present study focused on two patient subgroups:
(a) 635 patients with first-ever stroke (i.e., neither radiological
nor clinical evidence of prior stroke) and (b) 53 patients with
prior stroke (i.e., both clinical and radiological evidence of prior
stroke). Patients, who could not unambiguously assigned to
the first-ever or the recurrent stroke group on the basis of past
medical history and radiological signs, i.e., CS patients with
clinical but no radiological evidence of prior stroke or vice versa
(n= 243) were not included in the present study.
Statistical Analysis
The distribution of quantitative data is described by mean ±
standard deviation. Qualitative data is presented by absolute
and relative frequencies. Corresponding hypothesis testing was
performed by t-Test and the Chi-squared test or Fisher’s exact
test, as appropriate.
Missing values were imputed using a Random Forests
model to account for possible interactions and high-dimensional
relations of the data (20). Associations with prior stroke were
estimated by Odds Ratios, with 95% confidence intervals, using
univariate and multivariable logistic regression models. Any
model contained age as an independent variable to adjust for
confounding by the time-dependent stroke risk. Therefore, each
estimated effect is conditioned on age, i.e., the assessment of PFO-
related and—unrelated factors is valid for patients of the same age
who are consequently at the same time-dependent stroke risk.
The multivariable model was pre-specified to avoid bias and an
increased risk of data-driven false-positive findings (21).
A nomogram was developed to illustrate the effect size of
factors. Hypothesis testing was performed on exploratory two-
sided 5% significance levels.
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Of note, our main research goal was identification and effect
estimation of potential risk factors rather than hypothesis testing.
Moreover, the current study design did not allow for sample size
calculation and thus might not have been adequately powered to
test the multiple null hypotheses that the respective regression
coefficients are zero.
All analyses were performed using the statistical software
R 3.6.1 (The R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Factors Associated With Prior Stroke
Patient baseline characteristics are shown in Table 1. CS patients
with prior stroke were significantly older (64.8 ± 10.8 vs. 53.3
± 14 years), showed a higher body-mass-index (BMI, 27.8 ±
4.9 vs. 25.7 ± 4.5), were more likely to suffer from hypertension
(59 vs. 32%), diabetes mellitus (19 vs. 6%), hypercholesterolemia
(72 vs. 49%), and coronary artery disease (11 vs. 5%) and had a
higher portion of right-to-left shunt (RLS) at rest (43 vs. 28%)
compared to those with first-ever stroke. Adjusting for age, the
odds ratio for these factors in the univariable model was 1.07,
1.09, 2.93, 3.37, 2.67, 2.57, and 2.00 for RLS at rest, respectively
(Table 2). As expected, patients with prior stroke were frequently
on antithombotic (72 vs. first-ever stroke 12%), antihypertensive
(51 vs. 23%) and lipid lowering drugs (49 vs. 10%; all p< 0.0001).
The pre-specified multivariable logistic regression (Table 3)
demonstrated that prior stroke was strongly associated with
advancing age (OR 1.06, 95%CI 1.04–1.10, p < 0.001), RLS at
rest (OR 1.88, 95%CI 1.00–3.47, p= 0.046), hypercholesterolemia
(OR 1.90, 95%CI 1.00–3.73, p= 0.055) and BMI (OR 1.06, 95%CI
0.99–1.13, p = 0.074), reaching statistical significance for age
TABLE 2 | Association of baseline characteristics with prior stroke–univariate
analysis (missing values were imputed).
Predictor variable OR 95% CI P-value
Age, years 1.07 1.05–1.10 < 0.001
Male gender 0.86 0.48–1.52 0.617
Body-mass-index 1.09 1.03–1.14 0.002
Hypertension 2.93 1.67–5.25 < 0.001
Diabetes mellitus 3.37 1.51–6.96 0.002
Hypercholesterolemia 2.67 1.47–5.10 0.002
Smoking 0.73 0.35–1.40 0.365
Migraine 0.80 0.38–1.53 0.519
Coronary artery disease 2.57 0.93–6.11 0.045
Aortic plaque 2.32 0.53–7.26 0.192
Valsalva maneuver 0.22 0.01–1.04 0.138
Deep vein thrombosis 1.77 0.51–4.74 0.304
Pulmonary embolism 0.85 0.05–4.37 0.879
Right-to-left shunt at rest 2.00 1.12–3.53 0.017
Atrial septal aneurysm 1.18 0.65–2.10 0.568
OR, odds ratio; CI, confidence interval.
TABLE 1 | Baseline demographic, clinical and imaging data (missing values were imputed).
First-ever stroke n = 635 Missing values Prior stroke n = 53 Missing values P-value
Age, years 53.3 ± 14.0 – 64.8 ± 10.8 – <0.001
Male gender 262 (41.3) – 20 (37.7) – 0.722
Body mass index 25.7 ± 4.5 29 27.8 ± 4.9 2 0.003
Hypertension 206 (32.4) 1 31 (58.5) – <0.001
Diabetes mellitus 41 (6.5) 2 10 (18.9) – 0.003
Hypercholesterolemia 309 (48.7) 20 38 (71.7) 2 0.002
Smoking 168 (26.5) 16 11 (20.8) 2 0.456
Migraine 157 (24.7) 34 11 (20.8) 4 0.631
Coronary artery disease 30 (4.7) 8 6 (11.3) 1 0.050
Aortic plaque 16 (2.5) – 3 (5.7) – 0.174
Valsalva maneuver 51 (8.0) 57 1 (1.9) 4 0.169
Deep vein thrombosis 27 (4.5) 31 4 (7.7) 1 0.298
Pulmonary embolism 14 (2.3) 28 1 (1.9) 1 1.000
Right–to–left shunt at rest 176 (27.7) – 23 (43.4) – 0.024
Atrial septal aneurysm 215 (33.9) – 20 (37.7) – 0.674
Medication on admission
Antithrombotic therapy 77 (11.9) 38 (71.7) <0.001
Antiplatelet 66 35
Oral anticoagulation 11 3
Antihypertensive drugs 145 (22.5) 27 (50.9) <0.001
Lipid lowering drugs 65 (10.1) 26 (49.1) <0.001
Values are mean ± SD or n (%).
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TABLE 3 | Association of baseline characteristics with prior stroke–multivariable
analysis (pre-specified, missing values were imputed).
Predictor variable OR 95% CI P-value
Age, years 1.06 1.04–1.10 < 0.001
Male gender 0.78 0.41–1.46 0.446
Body-mass-index 1.06 0.99–1.13 0.074
Hypertension 1.06 0.53–2.11 0.872
Diabetes mellitus 1.45 0.58–3.42 0.413
Hypercholesterolemia 1.90 1.00–3.73 0.055
Smoking 1.35 0.61–2.82 0.439
Valsalva maneuver 0.28 0.02–1.39 0.218
Deep vein thrombosis 1.76 0.46–5.44 0.361
Right-to-left shunt at rest 1.88 1.00–3.47 0.046
Atrial septal aneurysm 0.98 0.51–1.84 0.959
OR, odds ratio; CI, confidence interval.
and RLS at rest. Moreover, the presence of a DVT (OR 1.76,
95%CI 0.46–5.44, p = 0.361) as well as an absent VM just before
stroke onset (OR 0.28, 95%CI 0.02–1.39, p = 0.218) also hinted
at a strong association with prior stroke, but was not statistically
significant in this cross-sectional analysis.
Considering the weight of each predictor variable in the
pre-specified multivariable model, reflected by its Odds Ratio,
we developed a nomogram to illustrate the strength of each
relation to prior stroke (Figure 1). Accordingly, age, BMI,
hypercholesterolemia, RLS at rest, absence of VM directly
preceding stroke onset and the presence of a DVT are the main
factors associated with stroke recurrence.
For example, a 55-year-old (+40points) female (+10p) CS
patient with PFO and an RLS at rest (+27.5p), BMI 30
kg/m2 (+50p), presence of VM just before stroke onset (0p),
sonographic proof of ASA (0p) and DVT (+25p), known
hypercholesterolemia (+27.5p), no arterial hypertension (0p) or
diabetes (0p) and non-smoker (0p) sums up to a total of 180
points, which corresponds to a likelihood of 7–8% that this
women belongs to the patient group with prior stroke.
DISCUSSION
The present analysis revealed associations of prior stroke with
both PFO-related and -unrelated risk factors. Our study gives a
novel insight into the nature and strength of the relationship of
previous strokes at presentation and PFO.
Previous clinical and/or radiological stroke at presentation has
been associated with higher risk of stroke recurrence in some
studies (18) but not in others (22). In addition, recent data suggest
that only CS patients with PFO in the high Risk of Paradoxical
Embolism (RoPE)- Score strata, i.e., absence of classical vascular
risk factors such as hypertension, diabetes mellitus and advancing
age show an association of prior stroke with stroke recurrence
(15). Age might play a dual role in the pathogenesis of stroke
recurrence—both as a PFO-unrelated and PFO-related factor.
It is usually considered a stroke risk factor that operates
through PFO-unrelated pathogenic mechanisms. The increasing
prevalence of classical vascular risk factors in older patients and
the fact that stroke recurrence after PFO closure was higher in
patients > 55 years of age than in younger patients underlines
the relevance of PFO-unrelated contributors to stroke recurrence
(23, 24). On the other hand, age might also increase the PFO-
related stroke risk by prolonging the exposure time to Right-to-
Left-Shunt. Prothrombotic conditions like endothelial damage,
hypercoagulability, chronic inflammation, and venous stasis due
to decreased regular exercise, which may not be addressed during
routine stroke workup or may even be undetectable, accumulate
with age and can predispose to paradoxical embolism in the long
term (25).
The association of PFO-related factors with stroke recurrence
has never been reliably established. Large PFOs have been
positively associated with stroke recurrence in some studies (26–
28) but not in others (14, 15, 29–31). The recent CLOSE and
DEFENSE trials (7, 9) enrolled carefully selected cryptogenic
stroke patients with large PFOs or concomitant atrial septal
aneurysm. The studies showed that PFO closure was more
efficacious in reducing the risk of stroke recurrence than
antithrombotic treatment alone. The GORE-REDUCE trial
included predominantly patients with moderate to large RLS
and likewise demonstrated the superiority of PFO closure
over medical treatment alone in preventing recurrent stroke
(8). In addition, recent meta-analyses of RCTs comparing
percutaneous PFO device closure with medical therapy in CS
patients further support device closure in patients with certain
PFO characteristics in particular moderate to large shunts
(32, 33). Since PFO closure cannot prevent strokes of other
possible etiologies, the findings of the above studies further
emphasize the role of PFO-related factors in the pathogenesis of
stroke recurrence.
Although our data suggest a strong association of prior stroke
with conditions predisposing to paradoxical embolism such as
DVT (OR 1.76) and VM directly preceding stroke onset (OR
0.28), the evidence is currently weak (DVT p = 0.361, VM
p = 0.218) and needs confirmation in prospective, adequately
powered trials. Briefly, the prevalence of DVT in the lower
extremities, which was systematically captured in our database,
was 4.4% in patients with first-ever stroke and 7.6% in patients
with prior stroke. The findings are in keeping with the results of
previous studies (34). However, we did not assess the prevalence
of pelvic vein thrombosis in all patients. Paradoxical emboli
originating from the pelvis have been recognized as an alternate
source of stroke in this population (35). The missing data on
pelvic vein thrombosis as well as the cross sectional study design
may have obfuscated a statistical significant association between
DVT and prior stroke.
VM at stroke onset was associated with a 72% reduced
likelihood of a previous ischemic event. This could be best
explained by the fact that VM increases RLS volume and supports
a causal relationship between stroke and PFO, i.e. the stroke is
most likely attributable to the PFO. PFO attributable strokes in
turn demonstrated a low recurrence rate (36).
In terms of PFO-unrelated factors, our study identified
hypercholesterolemia (OR 1.90, p = 0.055) and higher BMI
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FIGURE 1 | Nomogram: Likelihood of prior stroke in patients with cryptogenic stroke and PFO. Draw a line up perpendicular from the corresponding axis of each
predictor variable to the top line labeled “points.” Sum up the number of points for all predictor variables to receive “total points. Now, draw a line descending from the
“Total Points” axis until it intercepts the “Risk (%)” axis to estimate the likelihood of prior stroke.
(OR 1.06, p = 0.074) as being strongly associated with
prior stroke, albeit not adequately powered to demonstrate
statistical significance. Hyperlipidemia, especially an elevated
ratio of ApoE/A1 or non-HDL/HDL levels, are known risk
factors for ischemic stroke (37). Lipid-lowering drugs are firmly
established in secondary stroke prevention (38). Just recently,
it was shown that lowering LDL-levels below 1.8 mmol/l after
stroke/TIA reduces the risk of a subsequent cardiovascular event
compared to higher target LDL-levels (39), and the new ESC-
guidelines recommend even lower LDL-levels in selected high-
risk patients (40).
Several observational studies point to a lower rate of
stroke recurrence in overweight or obese patients (41–44).
However, recent studies in stroke patients receiving intravenous
thrombolysis or patients with mild symptoms did not detect
this relationship, thus challenging the “obesity paradox” (45,
46). Obesity was more common among patients with multiple
CS and PFO in a single study, though the recurrence risk
was not independently associated with BMI (18). Given these
controversial findings, the impact of BMI on stroke recurrence
needs further elucidation. Particularly in CS patients with PFO,
elevated BMI and the presence of obstructive sleep apnea (OSA)
might play a relevant role. Just recently, the coexistence of PFO
and OSA in overweight men was suggested as a risk factor
for wake-up stroke (47). Moreover, prolonged OSA episodes
promoted RLS occurrence during sleep, whichmight increase the
exposure time for paradoxical embolism (48).
The present study is limited by the missing assessment
of OSA and other potentially high-risk PFO characteristics
such as the presence of an Eustachian valve, a Chiari
network or left atrial enlargement (49). In addition, the
International PFO consortium study did not collect data
on history of migraine stratified into those with aura or
without. Furthermore, in patients with prior stroke, the PFO
features were assessed at the time of the recurrent stroke
only (i.e., at study enrollment). However, it is very unlikely
that shunt size or presence of ASA would have changed
substantially over time. Third, the process of screening for
PFO across the 19 participating stroke centers was not
standardized and thus might differ. Fourth, the effect of age
cannot be separated from the time-dependent stroke risk.
Therefore, age was mainly considered a confounder to allow
adjusted effect estimation of other risk factors considered in
the models.
Finally, we developed a nomogram to better illustrate the
effect size of each risk factor and to easily estimate the probability
of having suffered from a prior ischemic event at the time of the
index stroke. Several studies suggest that prior stroke might also
be associated with stroke recurrence (50, 51). Due to the cross
sectional design of our study, we are currently not able to firmly
establish those factors as risk factors for future events. However,
the present study allows to identify promising “risk factor”
candidates for recurrent stroke to be then tested in a longitudinal
study design.
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CONCLUSION
In CS patients with PFO, RLS at rest, hypercholesterolemia
and higher BMI were strongly related to prior stroke. The
likelihood of prior stroke is associated with both, PFO-related
and -unrelated factors. Based on the present findings, the impact
of these factors on stroke recurrence in CS patients with PFO
need to be further established in a longitudinal study design now.
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